Sofosbuvir (Sovaldi) sofosbuvir is indicated for the treatment of chronic hepatitis C virus (CHC) infection in adult patients with compensated liver disease, including cirrhosis
To perform a systematic review of the beneficial and harmful effects of sofosbuvir in combination with other agents for the treatment of adults with chronic hepatitis C virus (CHC) infection (genotypes 1, 2, 3, or 4)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2014, 2014 Oct
|
| Series: | Common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | To perform a systematic review of the beneficial and harmful effects of sofosbuvir in combination with other agents for the treatment of adults with chronic hepatitis C virus (CHC) infection (genotypes 1, 2, 3, or 4) |
|---|---|
| Item Description: | Title from HTML caption title |
| Physical Description: | 1 online resource illustrations |